Personalized Medicine
- 1st Edition, Volume 102 - January 28, 2016
- Imprint: Academic Press
- Editor: Rossen Donev
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 0 4 7 9 5 - 8
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 0 5 2 1 1 - 2
The Advances in Protein Chemistry and Structural Biology series is an essential resource for protein chemists. Each volume brings forth new information about protocols and analys… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteThe Advances in Protein Chemistry and Structural Biology series is an essential resource for protein chemists. Each volume brings forth new information about protocols and analysis of proteins, with each thematically organized volume guest edited by leading experts in a broad range of protein-related topics.
- Provides cutting-edge developments in protein chemistry and structural biology
- Chapters are written by authorities in their field
- Targeted to a wide audience of researchers, specialists, and students
Researchers and specialists in protein structure and interactions, cancer biology, psychiatry and mass spectrometry.
Chapter One: High-Performance Affinity Chromatography: Applications in Drug–Protein Binding Studies and Personalized Medicine
- Abstract
- 1 Introduction
- 2 Frontal Analysis Studies of Drug–Protein Interactions
- 3 Zonal Elution Studies of Drug–Protein Interactions
- 4 Other Methods for Examining Drug–Protein Interactions
- 5 Conclusion
- Acknowledgments
Chapter Two: Role of Proteomics in the Development of Personalized Medicine
- Abstract
- 1 Introduction
- 2 Protein Biomarkers
- 3 Protein Biochips
- 4 Role of Proteomics-Based Molecular Diagnostics in Personalized Medicine
- 5 Pharmacoproteomics
- 6 Concluding Remarks About Application of Proteomics for Personalized Medicine
Chapter Three: Metabolomics and Personalized Medicine
- Abstract
- 1 Introduction
- 2 The Value of “Omics” Technologies in the Development of Personalized Medicine
- 3 What is Metabolomics?
- 4 The Application of Metabolomics Toward Personalized Medicine
- 5 Concluding Remarks
- Acknowledgments
Chapter Four: Clinical Perspectives on Targeting Therapies for Personalized Medicine
- Abstract
- 1 Introduction
- 2 What Are Personalized Medicines?
- 3 Rare Diseases
- 4 Evidence for Precision Medicines from Real World Data
- 5 Using “Real World” Data
- 6 Ethical Concerns
- 7 Adaptive Trial Design
- 8 Companion Diagnostics
- 9 Biological Treatments
- 10 Case Studies: Targets for Precision Medicines and Companion Diagnostics
- 11 Network Pharmacology
- 12 Future Developments
- Acknowledgments
Chapter Five: Personalized Medicine in Respiratory Disease: Role of Proteomics
- Abstract
- 1 Introduction
- 2 Personalized Medicine
- 3 Proteomics
- 4 Respiratory Proteomics
- 5 Asthma
- 6 Chronic Obstructive Pulmonary Disease
- 7 Idiopathic Pulmonary Fibrosis
- 8 Aspirin-Exacerbated Respiratory Disease
- 9 Cystic Fibrosis
- 10 Lung Cancer
- 11 Conclusions
- Acknowledgments
Chapter Six: Computational Approaches to Accelerating Novel Medicine and Better Patient Care from Bedside to Benchtop
- Abstract
- 1 Introduction
- 2 Currently Approved Products Targeting Protein Kinases in Oncology
- 3 Tumor Heterogeneity
- 4 Computational Methods for Identifying Driver Mutations
- 5 Literature Mining in Oncology Research
- 6 Precise Genome Editing
- 7 Conclusion
- Supplementary Material
Chapter Seven: Molecular Dynamics: New Frontier in Personalized Medicine
- Abstract
- 1 Introduction
- 2 Single Nucleotide Polymorphisms in Drug Response
- 3 Drug Discovery
- 4 Advent of Personalized Medicine
- 5 Evolution of Molecular dynamics in the Field of Macromolecule and Binding Interaction Analysis
- 6 Molecular Dynamics—A Boon in Personalized Medicine
- 7 MD Trajectories Analysis
- 8 Application of MD in SNP Analysis Toward Drug Discovery
- 9 Plausible Ways to Overcome the Disadvantages of Molecular Dynamics
- 10 Conclusion
- Acknowledgments
Chapter Eight: Personalized Pharmacoperones for Lysosomal Storage Disorder: Approach for Next-Generation Treatment
- Abstract
- 1 Introduction
- 2 LSDs Classification
- 3 Treatment of LSDs
- 4 Pharmacological Chaperones Versus Chemical Chaperones
- 5 Combination Therapy for LSDs
- 6 How Can PCT Personalized?
- 7 Computational Studies in PCT
- 8 Advantages and Disadvantages of Various Therapies in LSDs
- 9 Future of PCTs
- 10 Conclusion
- Acknowledgments
Chapter Nine: Investigating the Inhibitory Effect of Wortmannin in the Hotspot Mutation at Codon 1047 of PIK3CA Kinase Domain: A Molecular Docking and Molecular Dynamics Approach
- Abstract
- 1 Introduction
- 2 Materials and Methods
- 3 Results
- 4 Discussion
- 5 Conclusion
- Acknowledgments
Chapter Ten: Role of von Willebrand Factor—A1 Domain Variants P1266L, H1268D, C1272R, and C1272F in VWD: A Molecular Modeling and Simulation Analysis Approach
- Abstract
- 1 Introduction
- 2 Material and Methods
- 3 Results
- 4 Discussion
- 5 Conclusion
- Acknowledgment
- Edition: 1
- Volume: 102
- Published: January 28, 2016
- No. of pages (Hardback): 398
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780128047958
- eBook ISBN: 9780128052112
RD
Rossen Donev
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.
Affiliations and expertise
Head of Research, MicroPharm Limited, UKRead Personalized Medicine on ScienceDirect